SeaStar Medical clears FDA post-approval study hurdle for QUELIMMUNE
SeaStar Medical has received confirmation from the US Food and Drug Administration's Centre for Biologics Evaluation and Research (CBER) that its QUELIMMUNE Paediatric SAVE Surveillance Registry has satisfied the post-approval study requirements attached to the original Humanitarian Device Exemption (HDE) granted in February 2024. The ruling lifts a significant operational constraint: hospitals can now deploy QUELIMMUNE without maintaining the research infrastructure that registry participation demanded, potentially opening access to intensive care units that were previously unable to participate.
QUELIMMUNE, based on SeaStar's Selective Cytopheretic Device (SCD-PED) technology, is indicated for critically ill paediatric patients aged 22 or under, weighing at least 10 kilograms, who have sepsis-associated acute kidney injury (AKI) and require renal replacement therapy (RRT). The company describes it as the only FDA-approved product for this ultra-rare condition.
Registry data
Data from the SAVE Registry, presented as a late-breaking poster at ASN Kidney Week 2026, underpinned the FDA's decision. The registry reported a 90-day survival rate of 65.1% among 43 patients treated with QUELIMMUNE, compared with 47.5% in a clinically aligned cohort of 196 patients drawn from the Kids' Inpatient Database, a large US all-payer paediatric inpatient dataset. The difference reached statistical significance at P = 0.043. Statistically significant improvements in in-hospital and 60-day survival were also observed. No device-related adverse events were recorded in the registry population.
Chief medical officer Kevin Chung noted the value of real-world evidence gathered through the registry: "The SAVE Registry gives us crucial real-world evidence on both safety and probable benefits in these patients, and we are grateful to the paediatric teams and families who made it possible."
It is worth noting that the HDE framework under which QUELIMMUNE was approved does not require demonstrated efficacy in the conventional sense; approval rests on safety and probable benefit. The FDA's standard disclaimer applies: effectiveness for this use has not been demonstrated. Known adverse reactions include hypotension, hypothermia, tachycardia, hyperglycaemia, and thrombocytopenia.
Market context and pipeline
The paediatric sepsis-associated AKI space remains extremely small by patient volume, which is precisely why the HDE route was available. SeaStar reports a background 90-day survival rate of roughly 50% with traditional supportive care, framing QUELIMMUNE's registry data as a clinically meaningful step forward. However, the absence of a randomised controlled trial in the paediatric setting means the comparative data rests on external database cohorts rather than a concurrent control arm, a methodological limitation that clinicians and health technology assessment bodies are likely to scrutinise when evaluating adoption.
SeaStar is simultaneously running the NEUTRALIZE-AKI pivotal trial, a 339-patient randomised study evaluating the adult SCD therapy in ICU patients with AKI on continuous RRT. That trial carries a composite primary endpoint of 90-day mortality or dialysis dependency. Positive results would materially expand the addressable market beyond the paediatric niche and validate the broader immunomodulatory platform. Investors will be watching the adult readout as the more commercially significant near-term catalyst, while the FDA's post-approval confirmation provides a reputational and operational foundation for the existing paediatric franchise.
SeaStar said it will continue to voluntarily enrol patients in the SAVE Registry at centres that choose to participate, with the aim of building further real-world evidence on optimal use of QUELIMMUNE across the paediatric critical care setting.